Company Filing History:
Years Active: 2016
Title: D Clive Williams: Innovator in Androgen Receptor Research
Introduction
D Clive Williams is a notable inventor based in Dalkey, Ireland. He has made significant contributions to the field of androgen receptor research, particularly in developing novel therapeutic strategies for prostate cancer treatment. His work focuses on non-ligand binding pocket antagonists for the human androgen receptor, which presents a promising alternative to traditional therapies.
Latest Patents
D Clive Williams holds a patent for "Androgen receptor ligands - Non ligand binding pocket antagonists for the human androgen receptor." This patent addresses the need for innovative treatments for androgen-dependent conditions, including prostate cancer. The androgen receptor plays a crucial role in modulating the effects of androgens like testosterone and dihydrotestosterone. Williams' research highlights a class of non-steroidal, small molecule AR antagonists that inhibit the transcriptional activity of the androgen receptor through non-ligand binding pocket-mediated modulation. This approach demonstrates full antagonism with low micromolar potency and high selectivity over estrogen and glucocorticoid receptors.
Career Highlights
Williams is affiliated with the College of the Holy and Undivided Trinity of Queen Elizabeth, near Dublin. His work has been instrumental in advancing the understanding of androgen receptor mechanisms and developing alternative therapies for prostate cancer. His innovative approach addresses the challenges posed by prolonged ligand binding pocket-targeting, which can lead to androgen resistance.
Collaborations
Williams has collaborated with notable colleagues, including David George Lloyd and Darren Fayne. Their combined expertise has contributed to the advancement of research in androgen receptor antagonism and therapeutic strategies.
Conclusion
D Clive Williams is a pioneering inventor whose work in androgen receptor research is paving the way for new treatment options for prostate cancer. His innovative patent and collaborative efforts reflect his commitment to advancing medical science and improving patient outcomes.